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 Chromodomain Helicase DNA-binding 
protein 4 (CHD4) is a chromatin-remodeling 
enzyme that has been reported to regulate DNA-
damage responses through its N-terminal region in 
a poly(ADP-ribose) polymerase dependent 
manner. We have identified and determined the 
structure of a stable domain (CHD4-N) in this N-
terminal region. The fold consists of a four α-helix 
bundle with structural similarity to the High 
Mobility Group (HMG) box, a domain that is well 
known as a DNA-binding module. We show that 
the CHD4-N domain binds with higher affinity to 
poly(ADP-ribose) than to DNA. We also show 
that the N-terminal region of CHD4, although not 
CHD4-N alone, is essential for full nucleosome 
remodeling activity and is important for localizing 
CHD4 to sites of DNA damage. Overall, these 
data build on our understanding of how 
CHD4/NuRD acts to regulate gene expression and 
participates in the DNA-damage response. 
   
 The nucleosome remodeling and 
deacetylase (NuRD) complex is a conserved 
transcription co-regulatory complex that is found 
in all complex animals. It is unique in that it 
contains both nucleosome remodeling and 
deacetylase activity (1-6); other co-regulator 
complexes such as Sin3 (7), Rpd3S (8) and PRC2 
(9) only carry a single enzymatic activity. The 
NuRD complex has been shown to have essential 
roles in both activation and repression of gene 
transcription and has links to stem cell renewal 
and differentiation (10), cell cycle control (11), 
cancer (reviewed in (12)) and the DNA-damage 
response (DDR), including DNA double-strand-
break (DSB) repair (13). DSBs are highly 
cytotoxic; if repaired erroneously or left 
unrepaired, they can lead to cancer, 
neurodegeneration and immunodeficiency (14). 
 One of the defining components of the 
NuRD complex is chromodomain helicase DNA-
binding protein 4 (CHD4). CHD4 mediates the 
chromatin remodeling activity of the NuRD 
complex via a SNF2-type DNA translocase 
domain (15) and evidence has accumulated that 
CHD4 is important for an effective DDR and for 
the maintenance of genomic integrity. For 
example, the expression level of CHD4 has been 
shown to increase upon UV irradiation (16). 
CHD4 has been also reported to be a target of the 
DDR apical kinases ATM and ATR (17-19) and to 
be recruited to DSB sites as part of the NuRD 
complex (20). This recruitment occurs in a 
poly(ADP-ribose) polymerase (PARP)-dependent 
manner. It has been shown that a 750-residue N-
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terminal fragment of CHD4 (residues 1-758) was 
sufficient for its recruitment and that this region 
binds poly(ADP-ribose) (PAR) polymers with the 
same apparent affinity as full-length CHD4 (20), 
suggesting that the N-terminal portion of CHD4 
contains one or more PAR-binding motifs. 
Similarly, the Drosophila homologue of CHD4 
(dMi-2) has been shown to be recruited to active 
heat shock genes in a PARP-dependent manner 
(21). Proteomic studies have also indicated that 
CHD4 and other proteins of the CHD family can 
undergo poly-ADP-ribosylation; however the 
biological effects of this modification are still 
unknown (22,23). 
 Poly(ADP-ribose) molecules are linear or 
multi-branched chains of ADP-ribose (ADPr). 
These polymers are synthesized by PARPs using 
NAD+ as a substrate, and are attached covalently 
to proteins as a post-translational modification 
(reviewed in (24)). Although still somewhat 
mysterious, PARylation has been shown to inhibit 
protein-protein and protein-DNA interactions, 
promote or alter protein localization, and regulate 
protein modifications such as ubiquitylation 
(reviewed in (25)). As signaling molecules, 
PARylated proteins have roles in a number of 
cellular processes, including DNA repair and 
programmed cell death. In recent years, several 
PAR-binding domains have been identified and 
their structures determined. For example, the DNA 
repair factor aprataxin polynucleotide-kinase-like 
(APLF) has been shown to interact with PAR 
through its two PAR-binding zinc-finger (PBZ) 
domains (26). The structure of the PAR-binding 
macrodomain, a module present in histone 
macroH2A1.1, has been determined in complex 
with ADPr (27). The apoptosis-inducing factor 
(AIF), which has a critical role in PARP1-
mediated cell death (28), has also been shown to 
bind PAR with high affinity; however, there is no 
structural information on this interaction. These 
data suggest that several distinct modes of PAR 
recognition exist and that interactions occur either 
through stacking between tyrosine/phenylalanine 
residues and the adenine rings or through 
electrostatic interactions between basic residues 
and the phosphate moiety of ADPr.  
 In addition to its SNF2 DNA translocase 
domain, CHD4 possesses two conserved 
chromodomains that are a feature of all CHD 
proteins and that are known to regulate the activity 
of the SNF2 domain (29) (Figure 1a). Two 
additional Plant HomeoDomains (PHDs) are 
present upstream of the chromodomains and are 
also found in the paralogues CHD3 and CHD5. 
The CHD4 PHDs bind the N-terminal tail of 
histone H3, exhibiting a preference for 
trimethylated or acetylated Lys 9 (30,31), and 
potentially conferring some substrate specificity to 
the CHD4/NuRD complex. Unlike CHD1 (32-34), 
which carries a DNA-binding SANT-SLIDE 
domains in the C-terminal region, CHD4 has not 
yet been shown to contain any C-terminal DNA-
binding domains. The N-terminal region of CHD4, 
which we define here as the ~360 residues 
upstream of the PHD domains, is conserved in 
CHD3/4 orthologues but absent in other members 
of the CHD family. This sequence lacks 
appreciable similarity to known domains and is 
rich in stretches of basic and acidic residues.  
 The focus of this study was to probe the 
role of the N-terminal region in the function of 
human CHD4. We identified a conserved domain 
in the N-terminal region of CHD4 (CHD4-N) and 
determined its three-dimensional structure by 
solution NMR spectroscopy. CHD4-N displays 
structural similarity to the High Mobility Group 
(HMG)-box fold, a known DNA-binding module 
that has roles in a wide variety of nuclear 
processes [reviewed in (35)], but no known 
affinity for PAR. We performed microscale 
thermophoresis (MST) assays and NMR 
experiments to assess the nucleic-acid binding 
properties of CHD4-N, and carried out chromatin 
remodeling assays and transient transfections 
coupled with laser micro-irradiation to assess 
whether the N-terminal region of CHD4 plays a 
role in localizing CHD4 to DSB sites. Our data 
show that the CHD4-N domain can recognize 
PAR and that the remainder of the N-terminal 
region of CHD4 enhances the chromatin 
remodeling activity of CHD4 and is important for 
directing CHD4 to DSB sites. 
 
EXPERIMENTAL PROCEDURES 
 Sequence analysis—Analysis of the N-
terminal sequence of CHD4 (1–364) was 
performed using a combination of multiple-
sequence alignments, secondary structure 
prediction in Jpred (36) and disorder predictions 
(37,38). 
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CHD4-N in bacteria—Residues 145–225 (CHD4-
N) of human CHD4 were cloned into a pGEX-6P 
vector to produce an N-terminal GST-fusion 
protein. CHD4-N was expressed in E. coli 
Rosetta 2 cells grown for 20 h at 25 °C in rich 
medium or, for isotope labeling, in minimal 
medium prepared as described previously (39). 
Cells were harvested and lysed and CHD4-N 
purified as described previously (39). CHD4-N 
has the additional sequence GPLGS on the N-
terminal end, a remnant from the protease 
cleavage site. Purified CHD4-N was assessed by 
SDS-PAGE and size-exclusion chromatography 
coupled to a multi-angle laser light scattering 
detector (SEC-MALLS). For NMR experiments, 
the protein was concentrated to 0.3–1 mM in a 
buffer comprising 20 mM sodium phosphate pH 
7.5 and 150 mM NaCl. D2O (5% v/v) and 2,2-
dimethyl-2-silapentane-5-sulfonic acid (DSS, 170 
µM, as a chemical shift reference) were added to 
the solution. 
 NMR assignments and structure 
calculations—NMR spectra were recorded at 
25 °C on 600 or 800 MHz Bruker Avance 
spectrometers equipped with TCI cryoprobes, 
processed using TopSpin™ (Bruker, Karlsruhe) 
and analyzed with SPARKY (T. D. Goddard and 
D. G. Kneller, University of California at San 
Francisco). 1H, 15N and 13C assignments were 
made using standard triple resonance spectra and 
backbone dihedral angles were calculated with 
TALOS+ (40), as described previously (39). 2D, 
15N-separated and 13C-separated NOESY spectra 
were analyzed to obtain distance constraints and 
initial structure calculations were performed using 
CYANA (41). From a family of 500 structures, the 
100 lowest energy structures were subjected to 
water refinement using the RECOORD protocol 
(42). The 20 lowest energy water-refined 
structures were analysed by PROCHECK NMR 
(43). Protein coordinates have been deposited in 
the Protein Data Bank under the accession code 
2n5n. 
 15N-HSQC titrations—All 15N-HSQC 
spectra were recorded at 25 °C. 15N-labeled 
CHD4-N was used at 50 µM [170 µM in the case 
of adenosine 5’-diphosphate (ADP, Sigma-
Aldrich)  titration] in buffer containing 20 mM 
sodium phosphate pH 7.5, 50 mM NaCl, 5% D2O 
and 0.17 mM DSS as a chemical shift reference. 
Titrations were performed with ADP, an ADP-
ribose dinucleotide (ADPr2, Sigma-Aldrich) or 
poly(A) (single stranded DNA ssA15, Integrated 
DNA Technologies) dissolved in the same buffer 
as CHD4-N. Spectra were recorded for CHD4-N 
alone and after each addition of ADP, ADPr2 or 
poly(A). Molar ratios of CHD4-N:ligand for 
which spectra were collected were 1:0, 1:0.5, 1:1, 
1:2, 1:5, 1:10. 15N-HSQC spectra were also 
recorded for 20 µM  15N-labeled CHD4-N in a 
buffer comprising 10 mM Tris pH 8 and 1 mM 
EDTA, in the presence or absence of poly(ADP-
ribose) (Trevigen®); the poly(ADP-ribose) was 
added to a concentration of  6 µM in ADP-ribose 
subunits. All spectra were processed using 
TopSpin™ (Bruker). 
 Microscale thermophoresis—MST 
experiments were performed on a Monolith 
NT.115 (Nanotemper Technologies, Munich, 
Germany). Each titration curve consisted of twelve 
points prepared from a serial dilution of CHD4-N 
and a constant concentration of the fluorescein-
labeled ligand. Experiments were carried out using 
50 nM fluorescein-labeled DNA (Integrated DNA 
Technologies); sequences tested were: (i) 15 
nucleotides (nt) of single stranded poly(A) (ssA15), 
(ii) 15-nt poly(T) (ssT15), and (iii) 15 base pairs of 
double stranded poly(AT) (prepared from ssT15 
and fluorescein-labeled ssA15 hybridized in-house 
and purified by size exclusion chromatography). 
Titrations with poly(ADP-ribose) were performed 
using a mixture of 200 nM fluorescein-labeled 
streptavidin (Vector Laboratories) and 1 nM 
biotinylated-PAR (Trevigen®). Commercially 
available PAR consists of a mixture of polymers 
that range from 2 to 300 subunits; the average of 
subunits per polymer was considered to be 150 for 
the purpose of concentration determination. MST 
assays were performed with 20, 50 or 100% LED 
power, using a blue filter and a 20 or 50% MST 
power. The normalized fluorescence readings were 
plotted as a function of CHD4-N concentration 
and fitted to a standard Langmuir binding 
isotherm, as implemented in the Nanotemper 
software. 
 Cloning of FLAG-CHD4 and FLAG-GFP-
CHD4 constructs—A pcDNA3 plasmid containing 
human chd4 and an N-terminal FLAG sequence 
was used to clone several mutant constructs. Using 
site-directed ligase-independent mutagenesis, 
described in (44), the truncated constructs CHD4-
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216 and 1–364, respectively, were created. The 
mutants CHD4-K757A and CHD4-α4A (which 
alters the sequence 202-
MMVLGAKWREFSTNN-216 to 
AMVLGAKAAEFSTAA) were produced using 
standard PCR mutagenesis. For live imaging 
experiments, we used the previously described 
human gfp-HA-chd4 construct in pCMV-Sport6 as 
the wild type construct (20). To clone the flag-gfp-
tagged versions of CHD4-ΔN, CHD4-Δ364 and 
CHD4-α4A, we used the method described by 
Gibson et al (45). 
 Laser micro-irradiation and live 
imaging—U2OS cells were cultured at 37 °C in a 
humidified atmosphere containing 5% CO2 in 
Dulbecco’s Modified Eagle Medium (DMEM; 
Sigma-Aldrich) supplemented with 10% (v/v) fetal 
bovine serum (FBS) from BioSera. Plasmid 
transfections were performed using TransIT-LT1 
(Mirus Bio) following the manufacturer’s 
guidelines. Localised lines of DNA damage were 
induced by laser micro-irradiation, essentially as 
described previously (46,47). Briefly, U2OS cells 
were plated on glass-bottomed dishes (Willco-
Wells), pre-sensitised with 10 µM BrdU (Sigma-
Aldrich) in phenol red-free medium (Invitrogen) 
for ~48 h at 37 °C. Subsequent exposure to a laser 
beam was performed using a FluoView 1000 
confocal microscope (Olympus) equipped with a 
37 °C heating stage (Ibidi) and a 405-nm laser 
diode (6 mW) focused through a 60× 
UPlanSApo/1.35 oil objective and resulting in a 
spot size of 0.5–1 µm. Laser beam exposure times 
of 250 ms (fast scanning mode) were used at a 
setting of 0.4 mW output (50 scans) to yield pre-
sensitisation-dependent DNA damage, restricted to 
laser tracks without detectable cytotoxicity. 
Images of live cells were acquired using the same 
microscope, objective and software as described 
above. For live-intensity quantifications of GFP-
CHD4 laser lines, average GFP-CHD4 intensities 
along laser tracks were measured and ratios of 
GFP-CHD4 average line intensities over average 
nucleoplasm intensities were calculated and 
compared using FV-10 software (Olympus). 
Approximately 10 cells were quantified per GFP-
CHD4 variant per time point. Normalised average 
intensities (1 for the GFP-CHD4-WT) are 
presented.  
 Expression and purification of FLAG-
CHD4 in mammalian cells—HEK293 cells were 
cultured at 37 °C in a humidified atmosphere 
containing 5% CO2 in DMEM, supplemented with 
10% (v/v) FBS, 2 mM L-glutamine, 1× minimum 
essential media non-essential amino acids, 1 mM 
sodium pyruvate, 50 U/mL penicillin and 
50 µg/mL streptomycin (all ingredients from 
Gibco™). pcDNA3 plasmids encoding for FLAG-
CHD4 constructs were transfected into HEK293 
cells at 70% confluence and CHD4 proteins were 
expressed for 48–72 h at 37 °C and 5% CO2. Cells 
were harvested and resuspended in 50 mM HEPES 
pH 7.5, 1.5 mM MgCl2, 10 mM KCl, 1 mM DTT, 
1 mM PMSF and 1× cOmplete EDTA-free 
protease inhibitor cocktail (Roche). Cells were 
incubated on ice for 30 min, vortexed and spun 
down for 5 min at 3300 g. The supernatant, which 
corresponds to the cytoplasmic fraction, was 
removed. The pellet was resuspended in 50 mM 
Tris pH 8, 0.5 M NaCl, 1 mM EDTA, 1% Triton-
X, 1.5 mM MgCl2, 1 mM DTT, 1 mM PMSF and 
1× EDTA-free protease inhibitors. The nuclear 
fraction was then lysed by sonication on ice, 
incubated on ice for 30 min to allow chromatin to 
precipitate and was cleared by centrifugation for 
20 min at 16000 g, at 4 °C. The resulting nuclear 
extract was then incubated with α-FLAG M2 
Affinity Gel beads (Sigma-Aldrich) overnight on a 
rocker at 4 °C. The next day, the protein was 
eluted with 300 µg/mL 3X-FLAG-peptide 
(ApexBio) in 20 mM HEPES pH 7.5, 150 mM 
NaCl, 1 mM DTT and 10% v/v glycerol. Protein 
samples were analysed by SDS-PAGE and 
visualized using SYPRO-Ruby and Coomassie 
stains. 
 Nucleosome reconstitutions—
Nucleosomes were assembled on DNA fragments 
derived from the 601 nucleosome positioning 
sequence (48) and purified recombinant Xenopus 
laevis histone octamers, to give a typical final 
nucleosome concentration of 1–2 µM. Assembly 
was performed by salt-gradient dialysis using a 
double-dialysis method (48), as follows. Reactions 
were placed in micro-dialysis buttons, which were 
placed inside a dialysis bag containing 30 mL 1× 
TE and 2 M NaCl; the dialysis bag was then 
dialysed overnight against 2 L of 1× TE at room 
temperature and then against a further 1 L of 1× 
TE for 3–6 h. 
 The histone octamers used in these 
reactions were assembled using standard protocols 
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as unlabelled proteins or containing 
AlexaFluor488-labelled H2A. Labelling of H2A 
was achieved via the incorporation of a single 
cysteine residue at position 120. A synthetic gene 
encoding H2A-T120C was purchased from 
GeneArt® and cloned into a rhamnose-inducible 
pRham vector (Lucigen). H2AT120C was 
expressed at 37 °C overnight in Rosetta2 (DE3) 
pLysS E. coli cells in ZYP-5052 auto-induction 
media (50) containing an additional 0.2% 
rhamnose and then purified from inclusion bodies 
using standard protocols (49). Labelling of 
purified H2A-T120C was performed under 
denaturing conditions in 20 mM Tris pH 7.0, 7 M 
guanidine-HCl, 5 mM EDTA, and 5 mM TCEP 
with a ~5-fold molar excess of AlexaFluor488 C5 
maleimide overnight at 4 °C. Reactions were 
quenched via the addition of 30 mM β-
mercaptoethanol and then purified via gel filtration 
on a Superdex 200 10/300 column in 20 mM Tris 
pH 7.0, 7 M guanidine-HCl, 0.1% β-
mercaptoethanol. Purified labelled H2A was 
dialysed against deionized water with 0.05% (v:v) 
β-mercaptoethanol overnight at 4 °C, aliquoted 
and lyophilised for long-term storage.  Labelling 
efficiency was ~65–70%.  
 DNA fragments were produced by PCR 
using MyTaq DNA polymerase (Bioline) and 
fluorophore/quencher labelled primers purchased 
from Sigma-Aldrich or ATDBio. The PCR 
products were purified via 0.5× TBE 5% 
polyacrylamide gel electrophoresis and 
electroelution. The notation xWy denotes the 147 
bp 601 sequence with flanking DNA of x and y bp 
on the upstream and downstream side, 
respectively. 
 ATP-driven nucleosome remodeling 
reactions—Nucleosomes were assembled on Cy3 
or BHQ1-labelled 0W47 DNA to generate 
asymmetric end-positioned nucleosomes for gel-
based and real-time remodeling reactions, 
respectively. All remodeling reactions were 
performed at 30 °C. Gel-based remodeling 
reactions were carried out essentially as described 
in (32). Real-time quenched FRET remodeling 
reactions were performed under similar conditions 
but monitored in a FluoStar Optima plate-reader 
using Corning black non-binding surface half-area 
96-well plates and 485P and 520P excitation and 
emission filters, respectively. The reactions 
contained 50 nM BHQ1-0W47 AlexaFluor488-
labelled nucleosomes, 50 mM Tris pH 7.5, 50 mM 
NaCl, 3 mM MgCl2, and the enzyme 
concentrations indicated in the figures. Reactions 
were monitored for 1 min prior to addition of 1 
mM ATP to ensure fluorescence changes were 
ATP-dependent and then monitored for a further 
5–10 min. The following single exponential 
function was fit to each individual remodeling data 
set: 
f(x) = a – b cx 
where a is the asymptote, b is the total response 
(i.e., a minus the starting value), and c a constant. 
The initial reaction rates were then calculated 
using the solution of the first derivative of f(x) 
when x =0, as follows:  
f’(0) = –b ln(c) 
Relative rates were calculated against the 
nominated control sample (e.g., wild-type CHD4 
or control treatment nucleosomes). 
 Nucleosome/DNA-stimulated PARylation 
reactions—PARylation and control reactions 
reactions were performed at room temperature for 
35 min. BHQ1-0W47 AlexaFluor488-labelled 
nucleosomes (0.5 µM) or an equimolar amount of 
free BHQ1-0W47 DNA were incubated in 50 mM 
Tris pH 7.5, 50 mM NaCl, 3 mM MgCl2 in the 
presence of 1 U/µL high-specific activity PARP1 
(Trevigen®) and 250 µM NAD+. Reactions were 
stopped via the addition of the PARP inhibitor 3-
aminobenzamide (3-AB) to 1 mM, either before or 
after the addition of PARP1. Control treatment 




 CHD4 contains a conserved domain at the 
N-terminus—Sequence analysis of CHD4 
(residues 1–364) revealed the presence of an 
eighty-residue region (145–225) that is highly 
conserved across complex animals (Figure 1b). 
For example, sequence identity between human 
and zebrafish CHD4 is ~90% in this region, 
whereas orthologues of CHD4 in plants lack this 
N-terminal region. The conserved sequence is 
predicted to encode a stable structure, according to 
secondary structure and disorder prediction 
software, suggesting that it might constitute a 
functional domain. We expressed and purified a 
polypeptide comprising human CHD4(145–225), 
which we termed CHD4-N, and used standard 
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dimensional structure. The solution structure 
obtained is of high precision, with a root mean 
square deviation (RMSD) over the backbone 
atoms of ordered residues (residues 150–217) of 
0.40 Å and, for all heavy atoms, 0.9 Å when the 
20 lowest energy structures are superposed (Figure 
2a). Experimental restraints and structural 
statistics are reported in Table 1. The CHD4-N 
geometry has no outliers according to the 
Ramachandran plot generated by PROCHECK 
NMR (43), suggesting that the CHD4-N structure 
is of high quality. 
 CHD4-N forms a helical bundle—The 
structure of CHD4-N consists of a four-helix 
bundle (Figure 2a). Helices 1 and 2 are on 
opposite sides of the domain and are separated by 
a long linker, whereas helices 2 and 3, and 3 and 4, 
are linked by short turns. Helix 1 packs against 
helix 4, which in turn packs against helix 3. At the 
helix 2 end, CHD4-N presents a hydrophobic core 
comprising H165 and F167 of the long linker; 
Y172 of helix 2; Y178, F181 and F184 of helix 3; 
and W209 and F212 of helix 4 (Figure 2b).  
Electrostatic surface charge analysis reveals the 
presence of two charged regions on opposite faces 
of the protein: a basic region along helices 3 and 4 
and an acidic region along the long linker (Figure 
2c). Although in principle this observation could 
indicate dimerization or oligomerization of CHD4-
N, SEC-MALLS data show that CHD4-N is 
monomeric in solution (Figure 2d). On the other 
hand, the combination of basic and acidic surfaces 
could suggest a possible interaction with 
chromatin in which the basic surface contacts 
DNA while the acidic region simultaneously 
makes interactions with the highly basic histone 
proteins. 
 CHD4-N is an HMG box-like domain—
Structure matching of CHD4-N, performed by the 
structure search engine PDBeFold 
(www.ebi.ac.uk/msd-srv/ssm/ssmstart.html), 
identifies the fold as similar to that of HMG-box 
domains. The HMG box is a versatile protein 
module that in general binds preferentially to 
distorted DNA structures (reviewed in (35)). This 
domain is found in both HMG-only-containing 
proteins or as part of multi-domain proteins, such 
as transcription factors or chromatin remodeling 
factors.  
 The three most similar HMG-box 
structures displayed 26% sequence similarity with 
CHD4-N and structural comparisons give RMSD 
values of between 1.2–1.5 Å over 38–39 Cα atoms 
(Figure 3a). All structural superpositions and 
sequence similarity occurred between the DNA-
binding region of the HMG box and helices 3 and 
4 of CHD4-N (Figure 3b-d), the helices that form 
a positively charged surface. These observations 
are consistent with the idea that the helix 3/4 
region might mediate binding to DNA. At the 
same time, our structural data demonstrate that 
there is no homology between CHD4-N and 
structurally characterized PAR-binding domains. 
 CHD4-N can bind DNA—In light of the 
structural similarity with the HMG-box domain 
and the reported PAR-binding activity of the N-
terminal portion of CHD4, 15N-HSQC titrations 
were performed in order to assess the binding of 
CHD4-N to nucleic acids. 15N-HSQC titrations 
using a single stranded DNA oligonucleotide 
revealed that CHD4-N can bind to a 15-nucleotide 
poly(A) homopolymer (ssA15, Figure 4a). We then 
used MST  to measure the affinity of CHD4-N for 
ssA15. In MST experiments, the diffusion of a 
fluorescently labelled macromolecule in a 
temperature gradient is measured in the presence 
of increasing concentrations of a binding partner 
(51). Changes in diffusion are plotted to create a 
binding isotherm. Titration of fluorescein-labelled 
ssAA15 with CHD4-N confirmed that the two 
species form a 1:1 complex with a dissociation 
constant, KD, of 32 ± 3 µM (Figure 4b). Similarly, 
MST experiments performed using single-stranded 
poly(T) (ssT15) showed 1:1 binding that fitted with 
a KD of 11 ± 1 µM (Figure 4c). These data suggest 
that CHD4-N is recognizing the DNA backbone 
structure rather than making specific interactions 
with the bases. To further assess DNA-binding 
specificity, MST assays were performed with the 
corresponding double stranded DNA [d(A.T)15]. 
The calculated KD in these assays was 13 ± 1 µM 
(Figure 4d), indicating that CHD4-N does not 
distinguish single-stranded from double-stranded 
DNA.  
 In order to explore whether sequences N- 
or C-terminal to the core CHD4-N domain 
influenced DNA-binding affinity, we expressed 
and purified eight polypeptides spanning different 
fractions of residues 1–355 of CHD4 (Figure 5). 
Two could not be expressed (1–310 and 1–355). 
Affinities for the interaction of each of the others 
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Figure 5. Overall, proteins with C-terminal 
extensions displayed ~10-fold higher affinity for 
ssA15 than CHD4-N. We selected the polypeptide 
with the highest affinity, CHD4(145–310), and 
also measured its binding to ssT15. Binding of 
CHD4(145-310) to ssT15 was also higher than for 
CHD4-N (2.7 µM compared to 11 µM, 
respectively). This indicates that the additional C-
terminal sequence that is rich in basic amino acids 
improved binding to ssDNA in a non-specific 
manner. 
 CHD4-N and HMG-box domains have 
similar binding surfaces—The DNA-binding 
properties of CHD4-N were further examined in a 
15N-HSQC titration with ssA15; up to 10 molar 
equivalents of ssA15 was added. The interaction 
was in fast exchange on the chemical shift 
timescale, and residues that had the largest 
chemical shift changes following the addition of 
DNA were K200, M201, M202, V204, L205, 
G206, A207, W209 and R210 (Figure 4e and 4f). 
This set of residues lies essentially on one surface 
of helix 4 of CHD4-N, the same surface that was 
predicted to interact with nucleic acids due to its 
basic surface charge and structural homology with 
other HMG-box domains.  
 CHD4-N binds PAR with higher affinity 
than DNA—Given the published observation that 
the N-terminal portion of CHD4 has PAR-binding 
activity, we performed binding experiments to 
determine if CHD4-N would bind to substrates 
that could mimic poly(ADP-ribose) molecules. 
Previously, PBZ domains of the APLF protein 
have been shown to bind similarly to ADP and 
ADP-ribose, but not to adenine alone (26), 
suggesting that the substrate recognition occurs at 
the ribose-phosphate moiety. However, 15N-HSQC 
titrations of 15N-CHD4-N with either ADP alone 
or a dinucleotide of ADP-ribose (up to 10 molar 
equivalents) did not give rise to any chemical shift 
changes. It is possible that ADPr2 is too short to 
effectively mimic PAR, so we therefore tested the 
binding of CHD4-N to polymers of ADP-ribose. 
Commercially available PAR consists of a 
heterogeneous mixture of oligomers and polymers 
of different lengths and branched architectures, 
ranging from an estimated 2 to 300 subunits. This 
heterogeneity prevents accurate determination of a 
molar concentration. We estimated the average 
size of PAR molecules to be 150 subunits and 
calculated concentrations on that basis. 
Biotinylated PAR was incubated with fluorescein-
tagged streptavidin and this complex used as the 
titrand in MST experiments with CHD4-N. MST 
data showed that CHD4-N binds PAR with an 
apparent KD of ~0.27 µM (Figure 6a), 
approximately 50 times tighter than the affinity for 
DNA. Note that because PAR was the titrand, the 
calculated KD does not differ significantly for 
different estimated polymer lengths between 2 and 
300 subunits. Further, the shape of the binding 
curve did not indicate the presence of 
cooperativity, even though multiple CHD4-N 
monomers could likely bind to a single PAR 
polymer.  
In contrast to the situation for DNA 
binding, the affinity of the longer CHD4(145–310) 
polypeptide for PAR was ~7-fold lower (2.0 µM) 
than was the affinity of CHD4-N. This effect 
could be due to the additional C-terminal residues 
preventing access to the PAR-binding site. Thus, 
these residues did not make a contribution to the 
interaction with PAR, suggesting that the minimal 
PAR binding region is the CHD4-N domain.  
 To confirm the binding of CHD4-N to 
PAR, we ran 15N-HSQC spectra of CHD4-N in the 
absence and presence of PAR (Figure 6b). 
Addition of PAR (the molar ratio of protein:PAR 
was 1:0.3 – only this quantity was available) gave 
rise to a range of selective changes in the CHD4-N 
spectrum. In this case, the timescale for binding to 
PAR appeared to be slower than for binding to 
DNA, consistent with the higher affinity. 
Additional line broadening might also arise from 
the high molecular weight of the PAR ligand, 
although carbohydrates typically display very fast 
internal dynamics compared to proteins, which 
would serve to mitigate this effect. The majority of 
the peaks that suffered chemical shift changes 
upon binding lie on the linker between helices 1 
and 2 and the surrounding surface (Figure 6c and 
6d), suggesting that the surface in CHD4-N 
involved in PAR binding is not the same as the 
surface that binds DNA.  
 The CHD4-N domain is not essential to 
recruit CHD4 to DSB sites—To evaluate the effect 
of CHD4-N on CHD4 recruitment to DNA 
damage sites, we performed laser micro-irradiation 
experiments in a similar manner to those described 
previously (20). It has been shown that, when laser 
micro-irradiation is used to generate localized 
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localizes with γH2AX, a well-established marker 
of DNA double strand breaks (DSBs), in a PARP-
dependent manner. We tested several GFP-tagged 
mutants of CHD4 in these experiments. CHD4-
WT corresponds to the full-length wild-type 
protein, CHD4-ΔN lacks the CHD4-N domain, 
CHD4-α4A is a full-length protein with five 
mutations to alanine on the DNA-binding surface 
of helix 4 of CHD4-N, and CHD4-Δ364 lacks the 
whole N-terminal region upstream of the PHD 
domains (Figure 7a). As shown in Figure 7b, GFP-
tagged-CHD4-WT, -CHD4-ΔN and -CHD4-α4A 
are effectively localized to the nucleus and 
accumulate at DSB sites with similar kinetics 
(Figure 7c). In contrast, GFP-CHD4-Δ364, which 
lacks both CHD4-N and the surrounding sequence 
that is predicted to be disordered, was present in 
both the nucleus and cytoplasm and was unable to 
accumulate at DSB sites.  
 Deletion of the N-terminal of CHD4 
reduces nucleosome remodeling activity—We next 
assessed the role of the N-terminal region of 
CHD4 in the nucleosome remodeling activity of 
CHD4. First, we purified full-length FLAG-tagged 
recombinant CHD4 from HEK293 cells using anti-
FLAG Sepharose beads. Then, we established that 
the purified protein was able to reposition 
nucleosomes in an ATP-dependent manner in a 
standard gel-based nucleosome repositioning 
assay. The addition of CHD4 and ATP to an 
asymmetric end-positioned nucleosome results in 
the appearance of a second band on a native DNA 
gel (Figure 8a), consistent with CHD4 centering 
the nucleosome through its intrinsic remodeling 
activity. To obtain a more quantitative estimate of 
CHD4 activity, we established a real-time FRET-
based nucleosome repositioning. This assay is 
similar to that described by Yang et al (52) except 
that the FRET dye pair has been modified to 
simplify measurements, increase throughput and 
improve sensitivity (manuscript in preparation).  
Briefly, asymmetric end-positioned nucleosomes 
with 0- and 47-bp linker DNA on each side were 
assembled in which the DNA was labelled on the 
0-bp linker with the dark quencher BHQ1. 
AlexaFluor488 was conjugated to a cysteine 
mutant (T120C) of histone H2A; this residue is 
close to the exit point of the DNA in the 
nucleosome (Figure 8b and 8c). The proximity of 
the BHQ1 moiety to the AlexaFluor488 in these 
nucleosomes results in strong quenching of 
AlexaFluor488 fluorescence. Any movement of 
the BHQ1 away from the AlexaFluor488 dye, such 
as during ATP-dependent repositioning by a 
remodeling enzyme, results in a robust increase in 
fluorescence that can be monitored in real time 
(Figure 8d).  
 Using these real-time remodeling assays 
we compared the repositioning activity of wild-
type CHD4, an inactive ATPase mutant (K757A), 
and the N-terminal mutants used in the laser 
microradiation experiments (proteins were 
expressed in HEK293 cells as FLAG-fusion 
proteins and purified by FLAG-affinity 
chromatography). As expected, the inactive 
ATPase mutant has no measurable repositioning 
activity, whereas wild-type CHD4, CHD4-ΔN and 
CHD4-α4A all robustly reposition nucleosomes at 
a similar rate. Interestingly, CHD4-Δ364 is a much 
less efficient enzyme and repositions nucleosomes 
at approximately 20% the rate of the wild-type 
protein (Figure 8e and 8f). 
 PARylation of nucleosomes/PARP1 
inhibits the nucleosome remodeling activity of 
CHD4—Given the interaction between CHD4 and 
PAR and that PARylation is a common 
nucleosomal modification (53-56), we next tested 
if PARylation has any effect on CHD4 remodeling 
activity. Real-time nucleosome repositioning 
assays were performed as above, except that the 
nucleosomes were treated with PARP1, NAD+ and 
the PARP1 inhibitor 3-aminobenzamide (3-AB) as 
outlined in Figure 9a. Repositioning assays were 
performed with wild-type CHD4 using either 
standard untreated nucleosomes, or nucleosomes 
treated with NAD+ and 3-AB alone (control 
treatment), or with NAD+ and PARP1 that was 
inhibited by 3-AB at the start of the treatment 
(inhibited PARP). Figure 9b shows that neither 
NAD+/3-AB nor inhibited PARP1 have a 
discernible effect on the rate of nucleosome 
repositioning by CHD4. In comparison, 
nucleosome repositioning by CHD4 is greatly 
reduced when nucleosomes have been pre-treated 
with active PARP1. These results indicate that 
PARylation, either of nucleosomes or PARP1 
itself, inhibits the remodeling activity of CHD4. 
PARylation of CHD4 cannot account for the 
observed effect as PARP1 is inhibited by 3-AB 
prior to encountering CHD4 in the repositioning 
assay. Furthermore, these effects are not due to 
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which look essentially identical in all cases by 
native PAGE.   
 Next, we assessed the activity of our N-
terminal mutants in these assays. Figure 9c shows 
that the relative rates of repositioning by the 
mutant proteins on control treated nucleosomes 
mirrors the pattern seen with untreated 
nucleosomes in Figure 8d, indicating NAD+ and 3-
AB do not affect the activity of the mutants. 
Treatment of nucleosomes with inhibited PARP1 
also does not lead to any significant changes in the 
rates of repositioning (Figure 9d, grey bars). In 
contrast, nucleosomes treated with active PARP1 
are repositioned much more slowly by either wild-
type CHD4 or by any of the mutants (Figure 9d, 
white bars). CHD4-Δ364 appears to be slightly 
less affected than the other mutants. However, it 
should be noted that the activity of CHD4-Δ364 is 
already significantly reduced compared to wild-
type (Figure 9c); the reduction shown in Figure 9d 
is in addition to that change, and equates to less 
than 10% of normal wild-type activity. Given that 
the trend is similar across all CHD4 mutants, these 
data suggest that the N-terminal region of CHD4 
does not specifically drive the PARylation-
dependent reduction of CHD4 activity. 
 The inhibition of remodeling we observe 
after treatment of nucleosomes with active PARP1 
could result from PARylation of the nucleosomes, 
PARP1 itself, or both. To investigate this issue, we 
set up PARylation reactions targeting PARP1 
only. It is known that PARP1 activity is stimulated 
by nucleic acids (54), and so PARylation reactions 
were performed essentially as described in Figure 
9a, except that the nucleosomes were substituted 
with free BHQ1-0W47 DNA. This treatment 
maintains stimulation of PARP1 activity but 
means that PARP1 itself is the only available 
substrate. Subsequently, PARP1 was inhibited 
with 3-AB and the material mixed with 
nucleosomes in preparation for real-time 
repositioning experiments. The final reaction 
mixture contained equimolar amounts of 
nucleosomes, free DNA and PARP1 at an 
equivalent concentration to previous experiments. 
Figure 9e shows that, in the absence of 
PARylation, all repositioning reactions proceed at 
essentially the same rate. Note that the presence of 
the free DNA itself partially inhibits CHD4 
activity (compare black dashed line with “+DNA” 
treatments), most likely by simple competition 
with nucleosomal DNA for CHD4 binding. In 
contrast, the presence of auto-PARylated PARP1 
(red curve) results in a marked decrease in the rate 
of nucleosome repositioning by CHD4 (compare 
red with blue curves). However, the level of 
inhibition achieved under these conditions is not 
as great as when both PARP1 and nucleosomes are 
available as PARP1 substrates (compare red line 
and dashed grey line). 
 
DISCUSSION 
 CHD4 contains an HMG-box like domain 
that can bind PAR—The CHD4/NuRD complex 
has been shown to be important in the DNA-
damage response. In particular, the N-terminal 
~750-residue region of CHD4 has been reported to 
be sufficient to recruit the NuRD complex to sites 
of damage (20). This same region was also able to 
bind PAR in immunoprecipitation experiments, 
suggesting that it would contain a PAR-binding 
motif. In addition, Drosophila melanogaster 
CHD4, which shares 30% similarity with human 
CHD4 in the corresponding region, was shown to 
interact in vitro with PAR through basic motifs in 
this region (21). We have identified a conserved 
and ordered domain at the N-terminal region of 
CHD4. This domain, CHD4-N, does not resemble 
other PAR-binding domains for which structures 
are known, but is instead related to HMG-box 
domains. In vitro binding assays show that CHD4-
N binds single stranded and double stranded DNA 
with similar affinities, suggesting that interactions 
with such ‘standard’ nucleic acids are probably not 
sequence-specific and most likely occur at the 
phosphate backbone. When compared to HMG-
box-DNA complex structures, CHD4-N helices 3 
and 4 superpose with the helices of HMG  box 
domains that are commonly involved in DNA 
binding. Our NMR data showed that this surface 
in CHD4-N was involved in DNA binding, 
suggesting that CHD4-N and HMG-box domains 
interact with nucleic acids in a similar way.   
 In contrast, even though CHD4-N bears 
no resemblance to known PAR-binding domains, 
we have demonstrated that CHD4-N can bind 
PAR in vitro. Despite the substantial heterogeneity 
of the PAR preparation used in these experiments, 
we can infer unequivocally both that the binding is 
direct and that it is non-cooperative. We can also 
infer that CHD4-N binds PAR with a higher 
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indicate that residues from the acidic linker 
between helices 1 and 2 of CHD4-N are most 
involved in the interaction with PAR, suggesting 
that the PAR-binding surface is distinct from the 
DNA-binding surface discussed above.  
The observation that CHD4-N did not 
bind to either monomeric or dimeric ADP-ribose 
suggests that recognition involves a structural 
element of PAR that is not present in these two 
moieties. The most likely candidate is the branch 
structure that is characteristic of PAR, in which 
the terminal ribose of an ADP-ribose unit connects 
to two additional units through both its C1' and C2' 
carbons. At this stage, however, the nature of the 
interaction cannot be deduced. Further analysis 
will require the chemical synthesis of specific 
PAR substructures and the purification of 
homogeneous preparations of PAR species, both 
processes that are technically challenging.
 Surprisingly, the corresponding HMG-
box-like region of Drosophila CHD4 did not show 
any interaction with PAR (21), but instead the 
basic sequences upstream and downstream of the 
HMG-box-like domain were sufficient to mediate 
PAR binding, suggesting that PAR-binding 
activity might be partitioned among several N-
terminal regions in CHD family members. 
 HMG boxes are known for their ability to 
recognize unusual nucleic acid structures—The 
HMG box is one of the most abundant chromatin-
binding domains in metazoans (57). Typically, 
these domains bind kinked or bent DNA 
structures, such as those found at entry or exit 
points to the nucleosome (57,58). HMG-box 
domains have not, however, previously been 
shown to bind poly(ADP-ribose). 
 Although we have shown that CHD4-N 
binds more tightly to PAR than to DNA, we 
cannot rule out that CHD4-N could be responsible 
for recognizing particular DNA structures, in an 
analogous fashion to HMG1/2. In addition, the 
sequence around CHD4-N harbours stretches of 
basic and acidic residues that could improve 
binding to DNA. Basic extensions at either the N 
or C-terminal of the HMG domain have been 
reported to increase the DNA-binding affinity and 
stabilize the bent conformation of DNA, as seen in 
the transcription factor LEF-1, the yeast 
chromatin-associated NHP6A protein and the 
Drosophila melanosgaster non-histone 
chromosomal HMG-D protein (59-61).  
 Furthermore, several other ATP-
dependent chromatin-remodeling complexes either 
contain or associate with HMG-box proteins (62-
66). In these cases, however, the nature of the 
nucleic acid targets of the HMG-box domains is 
not known. Sequence identity between these HMG 
domains and CHD4-N is ~20–25% around the 
DNA-binding helices 3 and 4, not sufficient to 
infer that these HMG domains could also bind 
PAR.  
 CHD4, PAR and chromatin remodeling—
In addition to its well-established connection with 
DNA repair, PARylation has also been shown to 
have effects in nucleosome remodeling; indeed, it 
is likely that these represent two faces of the same 
biochemical function. When ISWI is a target of 
poly-ADP-ribosylation, both ISWI ATPase 
activity and binding to DNA and nucleosomes are 
impaired (67). In contrast, the ATPase and 
chromatin remodeling activities of ALC1 are 
activated upon PARylation of PARP1 (68,69). 
This activation is a result of cooperative binding of 
PARylated PARP1 and ALC1 to nucleosomes. 
The interplay between PARylation and CHD4 
appears to be different again. Our data show that 
the remodeling activity of CHD4 is strongly 
inhibited in the presence of PARylation. Yet, 
unlike ISWI, it is not the remodeler that is 
PARylated but rather nucleosomes and/or PARP1 
itself. PARylated PARP1 is sufficient to elicit 
some inhibition, but the effect is enhanced when 
nucleosomes are also exposed to active PARP1, a 
situation that could result either from direct 
PARylation of nucleosomes or from nucleosomes 
acting as a greater stimulus of PARP1 activity 
(compared to free DNA). Further work is required 
to deconvolute these two possibilities. 
 Given our observation that the isolated 
CHD4-N domain binds PAR with sub-micromolar 
affinity, it was surprising that mutants targeting 
CHD4-N behaved largely like wild-type in 
response to PARylation in nucleosome 
repositioning assays. In addition, these mutants 
also had wild-type-like behaviour in the laser-
induced DNA damage experiments. Thus, CHD4-
N appears not to be necessary for the recruitment 
of CHD4 to DSB sites and the PARylation-
dependent inhibition of its nucleosome remodeling 
activity (at least on single nucleosomes). On the 
other hand, a larger region encompassing CHD4-N 
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accumulation of CHD4 at DSB sites and is also 
critical for the in vitro nucleosome repositioning 
activity of CHD4. 
 How does PARylated PARP1 inhibit 
CHD4 remodeling activity? One possibility is that 
binding of this species to CHD4 prevents it from 
binding nucleosomes, acting as a simple 
competitor in the same way free DNA also reduces 
CHD4 remodeling activity. Alternatively, binding 
to PARylated PARP1 might interfere directly with 
the catalytic cycle of CHD4, perhaps preventing a 
conformational change within the enzyme that is 
required for remodeling. Conversely, a direct 
PARP1-nucleosome interaction (PARylated 
PARP1 is known to bind nucleosomes (70)) might 
reduce the efficacy of CHD4 as a remodeller. 
 Finally, what is the biological context for 
this PARP1-mediated inhibition of CHD4 
activity? We offer two possible models. First, in 
the context of DNA-damage repair, the presence 
of PARylated PARP1 at specific loci (e.g., broken 
DNA ends) might demarcate sites at which CHD4 
should not act. In this scenario CHD4 would be 
recruited to damaged chromatin via PARylated 
PARP1, but be unable to directly remodel that 
chromatin. Instead, CHD4 action would be 
directed to areas up- and downstream of this site; 
either through interactions with other NuRD 
subunits or by subsequently being repositioned for 
action via the binding of its N-terminal region to 
other PARylated proteins. In addition, post-
translational modification of CHD4 might also 
have a role to play in regulating its activity in this 
context. CHD4 has already been shown to be 
phosphorylated in a DNA-damage-dependent 
manner (20). Second, it might be that the CHD4-
PARP1 interaction instead plays a role in the 
regulation of chromatin structure and gene 
transcription. PARP1 has been shown both to 
compact and to decondense chromatin under 
different circumstances, and also to both stimulate 
and inhibit the transcription of specific genes (71). 
Thus, PARP1 might act to antagonize CHD4 
activity in certain contexts. Choosing between 
these (or other) models will require a deeper 
understanding of the biochemical mechanisms 
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FIGURE LEGENDS 
 
Figure 1. CHD4 contains a conserved and uncharacterized N-terminal region. a) Domain organization of 
human CHD4 and the related yeast proteins ISW1 and CHD1. PHD, chromo (CHR) and SNF2-type 
helicase domains are shown, as well as the HAND, SANT and SLIDE DNA-binding domains. b) 
Sequence alignment of the N-terminal region of human CHD4 (1–364) and several eukaryotic 
orthologues. The secondary structure of CHD4-N is shown above the alignment. The sequence alignment 
was generated by ALINE (72). 
 
Figure 2. Structure of CHD4-N. a) Superposition of the 20 lowest-energy structures (Cα in red and side 
chains in green, left) and ribbon diagram (right) of CHD4-N. All four helices and the long linker 
connecting helices 1 and 2 are labeled. b) Residues involved in hydrophobic packing in the buried surface 
formed by helices 2, 3 and 4. CHD4-N is viewed as from the top of panel a) after a 45° clockwise 
rotation. c) Electrostatic surface charge of CHD4-N. Left panel is in the same orientation as a). d) SEC-
MALLS data for CHD4-N. The expected molecular mass for the domain is 9290 Da. The average 
molecular weight of the eluted peak is 9800 ± 150 Da. 
 
Figure 3. CHD4-N has an HMG-box-like fold. a) Superposition of CHD4-N (red) with the HMG-box 
domain from several proteins: yeast NHP6A (PDB 1j5n, light grey), fly HMG-D (PDB 3nm9, dark grey) 
and mouse HMGX2 (PDB 2crj, black). b) Structure and electrostatic surface charge of the complex of 
NHP6A bound to SRY DNA (PDB 1j5n). The protein is shown in the same orientation as a). c) 
Alignment of CHD4-N (red) and NHP6A (grey), showing conserved residues across helices 3 and 4 of 
CHD4-N as highlighted in the alignment d). d) Sequence alignment of CHD4-N and various eukaryotic 
HMG-box domains (UniProt entry numbers in brackets). CHD4-N secondary structure is shown in red 
above the alignment, and residues involved in DNA-binding for NHP6A (b) and for CHD4-N (Figure 4e) 
are indicated with green and yellow diamonds, respectively. The sequence alignment was generated by 
ALINE (72). 
 
Figure 4. CHD4-N binds DNA. a) 15N-HSQC titration of 15N-CHD4-N with ssA15. Spectra corresponding 
to protein:DNA molar ratios of 1:0 to 1:10 are shown. b)–d) MST titration experiments of CHD4-N with 
b) ssA15, c) ssT15 and d) d(A.T)15. MST graphs show representative experiments. KDs are given with the 
standard error of the mean (s.e.m.) from at least three independent experiments. e) Chemical shift (CS) 
changes (calculated as in (73)) for CHD4-N residues upon addition of 10 molar equivalents of ssA15. 
Residues that underwent CS changes of more than |CSCmean + 1σ| are highlighted in yellow. f) CHD4-N 
coloured according to the same colour scheme as in e). The structure is in the same orientation as in 
Figure 2a. 
 
Figure 5. Longer CHD4 polypeptides bind DNA. Constructs that were designed to encode longer 
segments of the N-terminal part of CHD4, as shown, were designed, expressed and purified. Their affinity 
for ssA15 was measured by MST. KD values from two independent measurements (one carried out with 
the corresponding cleaved protein or with the GST-fusion protein, respectively) are shown. 
 
Figure 6. CHD4-N binds PAR with higher affinity than DNA. a) A representative MST titration of 
poly(ADP-ribose) with CHD4-N. The KD is given with the s.e.m. from five independent experiments. The 
no PAR titration refers to a control experiment where the streptavidin-biotin-PAR was substituted by 
streptavidin alone. b) 15N-HSQC of 15N-CHD4-N in the absence (red) and in the presence (blue) of PAR. 
c) Chemical shift changes (CSC, calculated as in (73)) for CHD4-N residues upon addition of 0.3 molar 
equivalents of PAR. Residues that underwent CS changes of more than |CSCmean + 1σ| are highlighted in 
yellow. Residues for which peaks disappeared or became significantly more intense are marked with cyan 
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15N-HSQC are perturbed following the addition of PAR. The same colour scheme as in c) is used. Top 
panel structure is in the same orientation as in Figure 2a. 
 
Figure 7. The CHD4-N domain is not essential for the recruitment of CHD4 to DNA damage sites but the 
N-terminal region of CHD4 has a nuclear localization role. a) Diagram of the CHD4 constructs tested. 
The crosses indicate approximately the sites of mutagenesis – five alanine mutations for CHD4-α4A and 
one Ala mutation for CHD4-K757A. b) Live imaging of GFP-CHD4 variants, at the indicated time 
points, following laser micro-irradiation in U2OS cells. The nucleus of each cell is outlined with a dashed 
white line. c) Quantification of GFP-CHD4 recruitment at the DSB site. Average fluorescence intensities 
were normalised relatively to the wild-type protein. Error bars are from the standard deviation calculated 
for a population of n=10. 
 
Figure 8. Deletion of the CHD4 N-terminal region reduces nucleosome repositioning activity. a) Native 
PAGE (0.5× TBE, 5% acrylamide) analysis of nucleosome repositioning assays using recombinant 
human CHD4. End-positioned Cy3-labelled 0W47 nucleosomes (50 nM) were incubated for 30 min with 
different amounts of enzyme (1 or 10 nM) with or without ATP. The gel was scanned for Cy3 
fluorescence. b) Structure of the nucleosome core particle (PDB 1kx5) showing dye attachment sites used 
in real-time repositioning experiments (H2A is shown in blue; H2B, H3, and H4 in grey; DNA in orange). 
The dark quencher BHQ1 (purple) is attached to the 5’end of the DNA and AlexaFluor488 (green) is 
attached via maleimide linkage to Cys120 in H2AT120C. c) Schematic representation of the ATP- and 
remodeller-dependent movement of the BHQ1 dye relative to AlexaFluor488. In the starting asymmetric 
(0W47) nucleosomes, the proximity of BHQ1 to the AlexaFluor488 moiety results in strong quenching of 
AlexaFluor488 fluorescence. Movement of BHQ1 away from the AlexaFluo488 during remodeling 
releases quenching and AlexaFluor488 fluorescence emission consequently increases. Colouring is the 
same as in b). d) Nucleosome remodeling activity is dependent on the concentration of CHD4. Real-time 
fluorescence repositioning traces (520 nm) for 50 nM BHQ1-0W47 AlexaFluor488-H2A nucleosomes 
recorded in the presence of increasing CHD4 concentrations. e) Real-time repositioning traces of BHQ1-
0W47 AlexaFluor488-H2A nucleosomes (50 nM) recorded in the presence of 10 nM wild-type CHD4 or 
the indicated CHD4 mutants. f) Relative rates of repositioning of 50 nM BHQ1-0W47 AlexaFluor488-
H2A nucleosomes by CHD4 mutant proteins in comparison to wild-type CHD4. Data are the average of 
four experiments using 10 nM enzyme. Error bars represent the s.e.m. Large errors for K757A are due to 
the model inadequately fitting the essentially null data and not large fluctuations in the data itself. 
 
Figure 9. PARylation of PARP1/nucleosomes inhibits nucleosome repositioning by CHD4. a) Scheme 
outlining the treatment of nucleosomes with ‘active’ or ‘inhibited’ PARP1 used to generate PARylated 
and control substrates for real-time nucleosome repositioning assays. b) Real-time nucleosome 
repositioning data for 10 nM wild-type CHD4 and 50 nM BHQ1-0W47- and AlexaFluor488-H2A-
labelled nucleosomes derived from untreated stock or pretreated as described in a). Only nucleosomes 
incubated with active PARP1 give rise to reduce nucleosome repositioning activity by CHD4. Note that 
data for the ‘untreated’ and ‘control treatment’ samples are directly underneath the ‘inhibited PARP1’ 
curve and therefore not visible. c) Rates of repositioning of control treatment nucleosomes by CHD4 N-
terminal mutant proteins relative to that of wild-type CHD4. Data are the average of three experiments 
and are recorded using the same conditions as in b). d) Relative rates of repositioning of nucleosomes 
treated with active or inhibited PARP1 expressed as a fraction of the rate of repositioning of control 
treated nucleosomes (shown in part c)) using the same mutant. Data are the average of three experiments. 
All error bars represent the s.e.m. e) PARylated PARP1 inhibits CHD4 remodeling activity. DNA was 
used to stimulate PARP1 activity under active or inhibited conditions, essentially following the scheme 
described for nucleosomes in a) and added to real-time fluorescence repositioning traces for 50 nM 
BHQ1-0W47 AlexaFluor488-H2A nucleosomes recorded in the presence of 10 nM CHD4 and 1 µM 
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magenta line shows that nucleosome repositioning is inhibited only to a small degree by free PAR 
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NOE-based distance constraints   
    Total 1291 
    Intraresidue (i,i) 344 
    Sequential (i, i+1) 307 
    Medium-range (2 ≤ |i-j| ≤ 4) 298 
    Long-range (|i-j| > 4) 342 
Total dihedral angle constraints 133 
RMS deviation from lowest energy structure  
    All backbone atoms (N, Cα, C’)(Å) 3.2 
    All heavy-atoms (N, C, O, S) (Å) 3.1 
PROCHECK Ramachandran statistics  
    Residues in most favored region (%) 92.9 
    Residues in additional allowed regions (%) 7.1 
    Residues in disallowed regions (%) 0 
Deviation from idealized geometry  
    Bond lengths (Å) 0.012 
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KD = 32 ± 3 μM
ssT15
KD = 11 ± 1 μM
d(A.T)15
KD = 13 ± 1 μM
W158sc


















1H  chemical shift (ppm)












































































KD = 0.27 ± 0.07 μM
α1-α2 linker














1H  chemical shift (ppm)
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